ADVERTISEMENT

Ezetimibe combined with moderate-intensity statin may benefit some with diabetes

Miriam Tucker   |   Clinical Summary   |   29 December 2022
ADVERTISEMENT

The combination could represent an alternative for those who can’t tolerate high-intensity statin monotherapy.

Takeaway

  • In patients with diabetes and atherosclerotic cardiovascular disease (ASCVD), ezetimibe combined with moderate-intensity statin therapy was comparable to high-intensity statin monotherapy in terms of cardiovascular event outcomes.
  • The combination was associated with lower intolerance-related drug...

          

Topic Challenges

left
right